A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
MK-0941
Placebo
Insulin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Participant has Type 2 Diabetes Mellitus
Exclusion Criteria:
- Participant has a history of Type 1 Diabetes Mellitus or ketoacidosis
- Participant is on a weight loss program and is not in the maintenance phase or is taking a weight loss medication
- Participant has had surgery within 30 days of starting the study or has planned major surgery
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
MK-0941
Arm Description
Participants receiving placebo tablets three times daily plus insulin injection once daily
Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
Outcomes
Primary Outcome Measures
Change From Baseline in Hemoglobin A1c (HbA1c) Level
HbA1c level is a blood test measurement of the amount (percent) of hemoglobin that is glycated (or has glucose on it). HbA1c level is related to the average blood glucose concentration over the previous 2-3 months, with a higher HbA1c level indicating a higher amount of average plasma glucose. A negative number for change from baseline in HbA1c level means a reduction in HbA1c level and indicates better control of average plasma glucose levels.
Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)
Hypoglycemic episodes - with or without symptoms - are defined as a fingerstick glucose measurement of ≤70 mg/dL (3.9 mmol/L). Excludes data after initiation of glycemic rescue therapy.
Secondary Outcome Measures
Full Information
NCT ID
NCT00824616
First Posted
January 16, 2009
Last Updated
July 21, 2015
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00824616
Brief Title
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
Official Title
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
68 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants receiving placebo tablets three times daily plus insulin injection once daily
Arm Title
MK-0941
Arm Type
Experimental
Arm Description
Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
Intervention Type
Drug
Intervention Name(s)
MK-0941
Intervention Description
MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablets, taken 3 times daily.
Intervention Type
Drug
Intervention Name(s)
Insulin
Other Intervention Name(s)
LANTUS®
Intervention Description
Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
Primary Outcome Measure Information:
Title
Change From Baseline in Hemoglobin A1c (HbA1c) Level
Description
HbA1c level is a blood test measurement of the amount (percent) of hemoglobin that is glycated (or has glucose on it). HbA1c level is related to the average blood glucose concentration over the previous 2-3 months, with a higher HbA1c level indicating a higher amount of average plasma glucose. A negative number for change from baseline in HbA1c level means a reduction in HbA1c level and indicates better control of average plasma glucose levels.
Time Frame
Baseline (Day 1) and End of Treatment (Week 20)
Title
Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)
Description
Hypoglycemic episodes - with or without symptoms - are defined as a fingerstick glucose measurement of ≤70 mg/dL (3.9 mmol/L). Excludes data after initiation of glycemic rescue therapy.
Time Frame
From first dose of study drug (Week 0) to last dose of study drug (Week 20)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participant has Type 2 Diabetes Mellitus
Exclusion Criteria:
Participant has a history of Type 1 Diabetes Mellitus or ketoacidosis
Participant is on a weight loss program and is not in the maintenance phase or is taking a weight loss medication
Participant has had surgery within 30 days of starting the study or has planned major surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
We'll reach out to this number within 24 hrs